|
The market doesn't look dramatic on the surface. The S&P 500 is roughly flat year to date. But underneath, there's real turbulence. |
AI leaders have cracked. Software has seen sharp single-session drawdowns. Crypto liquidations have spilled into equities. Volatility is creeping higher. |
When sentiment shifts this quickly, investors stop distinguishing between temporary pressure and structural damage. |
That's where opportunity shows up. |
Right now, I'm focused on five companies that have sold off meaningfully from their 52-week highs. That decline matters. It tells us expectations have reset. The question is whether the businesses themselves have deteriorated or whether price simply moved faster than fundamentals. |
In these cases, I believe the selloff is disconnected from long-term fundamentals. |
Here's where I'm putting capital and why. |
Amazon (AMZN) |
Down sharply from highs… An investment cycle, not deterioration |
Amazon has pulled back materially from its 52-week high after signaling significant AI and infrastructure spending. The market reacted the way it usually does when capex spikes: it assumed margin compression equals trouble. |
|
I see it differently. |
Amazon is in a heavy investment phase. Capex pressures near-term free cash flow. But historically, these phases have preceded stronger earnings cycles once capacity monetizes. |
Revenue growth remains steady. More importantly, EBITDA and EPS have grown faster than revenue over time, which signals operating leverage is still working. Return on equity remains solid. The balance sheet is manageable. AWS backlog continues to expand. |
This is not a broken business. It is a dominant platform reinvesting aggressively. |
What would change my view? If AWS growth decelerates materially and backlog fails to convert into revenue, then the multiple deserves compression. That's the variable that matters. |
At current levels, well off the highs the valuation compensates for that risk. |
My stance: I'm buying Amazon into weakness with a 12–24 month horizon. |
UnitedHealth (UNH) |
A sharp reset… Regulatory fear vs durable economics |
UnitedHealth has fallen significantly from its 52-week peak following reimbursement concerns and regulatory scrutiny. |
Healthcare names often sell off hard when policy headlines hit. But the underlying economics rarely shift overnight. |
|
UnitedHealth still generates consistent revenue growth, strong cash flow, and durable returns on capital. Its Optum platform continues to expand. Its scale remains unmatched in managed care. |
The spike in medical loss ratio pressured margins. That is cyclical. The real risk would be structural reimbursement compression that permanently alters profitability. |
At this stage, that outcome looks overstated relative to the company's long-term earnings power. |
When a defensive, cash-flowing operator with scale trades well below prior highs on policy fear, I pay attention. |
My stance: I'm accumulating UNH gradually at these levels. |
Novo Nordisk (NVO) |
A meaningful pullback… Growth pause, not growth peak |
Novo has declined materially from its highs amid pricing pressure concerns and intensifying GLP-1 competition. |
|
Competition from Eli Lilly is real. This is a competitive market now. But the broader obesity and diabetes markets are still expanding globally at a significant pace. |
Novo continues to deliver strong multi-year revenue growth, exceptional return on equity, and industry-leading gross margins. Free cash flow remains robust. The balance sheet remains solid. |
Key variables I'm watching: |
U.S. pricing developments
Pipeline execution on next-generation formulations
Market share dynamics versus competitors
|
If pricing stabilizes and pipeline execution continues, current levels well below prior highs offer attractive long-term risk-reward. If competitive pressure accelerates materially, the thesis would need reassessment. |
Right now, I see a high-quality franchise trading at a discount created by sentiment. |
My stance: I'm building a position on this pullback. |
At this point, I've covered three large-cap names where I believe the market has overreacted. | The next two ideas are different. | They're smaller. More volatile. And the upside, in my view, is significantly asymmetric especially given how far they've fallen from their highs. | I'm going to break down those final two picks next, including why I believe the selloff is temporary and what needs to happen for the recovery to play out. | If you're reading this as a guest, enter your email below and I'll send you the full breakdown immediately. |
|
|
Want the Full Framework? | This article is a small glimpse into how I evaluate opportunities during periods of market dislocation. | Inside our paid service, we go deeper. | We don't just discuss ideas. We provide: | | Right now, I've put together a special report outlining my Top 3 highest-conviction stocks, supported by both fundamental analysis and insider accumulation signals. | I also recorded a full breakdown video explaining: | How I use insider buying patterns
How I identify dislocations before they reverse
And exactly how members get positioned
| If you want access to that research and the full framework behind it, you can watch the video and learn more about joining here. | Volatility creates opportunity. | The key is knowing where to look — and how to act when you find it. | |
|
|
 |
The Most Valuable Part of This Report Is Just Ahead |
To continue reading this premium analysis, unlock full access below. |
|
Upgrade now and get the full article along with these benefits: |
• Trade Setups That Work Risk-defined strategies built on insider activity, volatility behavior, momentum shifts, and liquidity dynamics. |
• Macro Intelligence and Sector Rotations Early-stage insights into AI infrastructure, defense cycles, energy trends, and emerging tech opportunities. |
• Priority Access to Our Best Ideas Deep-dive reports, bonus stock picks, and premium research you will not find in the free feed. |
Post a Comment
Post a Comment